Literature DB >> 9880399

Adenovirus-mediated gene transfer is augmented in basilar and carotid arteries of heritable hyperlipidemic rabbits.

D D Lund1, F M Faraci, H Ooboshi, B L Davidson, D D Heistad.   

Abstract

BACKGROUND AND
PURPOSE: There are major differences in susceptibility of intracranial and extracranial arteries to atherosclerosis. The goal of this study was to examine adenovirus-mediated gene transfer to basilar and carotid arteries of Watanabe heritable hyperlipidemic (WHHL) rabbits, which have spontaneous hypercholesterolemia and atherosclerosis, and normal New Zealand White (NZW) rabbits. We used 2 different adenoviral vectors, driven by either cytomegalovirus (CMV) or Rous sarcoma virus (RSV) promoters.
METHODS: Basilar and carotid arteries were removed from WHHL and NZW rabbits and cut into rings. The arteries were incubated with an adenoviral vector that expresses beta-galactosidase and is driven by either a cytomegalovirus (CMV) or Rous sarcoma virus (RSV) promoter (AdCMVbetagal or AdRSVbetagal). Arteries were incubated with virus for 2 hours, and then incubated in medium for 24 hours to allow expression of transgene. Transgene expression was assessed by enzyme activity (Galacto-Light assay) and by a histochemical method after X-Gal staining.
RESULTS: After gene transfer, beta-galactosidase was expressed in endothelium and adventitia but not media. There were moderately severe atherosclerotic lesions in carotid arteries and early lesions in basilar arteries. Enzyme activity after gene transfer with AdCMVbetagal (3x10(11) particles/mL) was greater in the basilar artery of WHHL than NZW (137+/-40 versus 25+/-10 mU/mg protein, P<0.05) (mean+/-SE) and in the carotid artery (133+/-27 versus 34+/-11 mU/mg protein, P<0.05). After gene transfer with AdRSVbetagal, transgene expression was similar in arteries from WHHL and normal NZW rabbits.
CONCLUSIONS: This is the first study to examine gene transfer to intracranial and extracranial arteries from atherosclerotic animals. The findings suggest that an adenoviral vector with a CMV, but not RSV, promoter provides greater transgene expression in the basilar and carotid arteries from spontaneously atherosclerotic rabbits than from normal rabbits.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9880399     DOI: 10.1161/01.str.30.1.120

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  7 in total

Review 1.  The future of gene therapy for stroke.

Authors:  C A Gunnett; D D Heistad
Journal:  Curr Hypertens Rep       Date:  2001-02       Impact factor: 5.369

2.  Effects of chronic administration of the novel endothelin antagonist J-104132 on endothelial dysfunction in streptozotocin-induced diabetic rat.

Authors:  Noriyasu Kanie; Katsuo Kamata
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

3.  Relationship between peroxisome proliferator-activated receptors (PPAR alpha and PPAR gamma) and endothelium-dependent relaxation in streptozotocin-induced diabetic rats.

Authors:  Noriyasu Kanie; Takayuki Matsumoto; Tsuneo Kobayashi; Katsuo Kamata
Journal:  Br J Pharmacol       Date:  2003-07-29       Impact factor: 8.739

4.  Age-related neuronal vulnerability to brain ischemia: A potential target of gene therapy.

Authors:  H Ooboshi; S Ibayashi; H Yao; J Takada; D D Heistad; M Fujishima
Journal:  J Am Aging Assoc       Date:  2001-01

Review 5.  Gene therapy for cerebral vascular disease: update 2003.

Authors:  Kazunori Toyoda; Yi Chu; Donald D Heistad
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

6.  Enhanced cytomegalovirus infection in atherosclerotic human blood vessels.

Authors:  Pamela L Nerheim; Jeffery L Meier; Mohammad A Vasef; Wei-Gen Li; Ling Hu; James B Rice; Daniel Gavrila; Wayne E Richenbacher; Neal L Weintraub
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

7.  The History of the WHHL Rabbit, an Animal Model of Familial Hypercholesterolemia (II) - Contribution to the Development and Validation of the Therapeutics for Hypercholesterolemia and Atherosclerosis.

Authors:  Masashi Shiomi
Journal:  J Atheroscler Thromb       Date:  2019-11-21       Impact factor: 4.928

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.